# A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.

> **NCT07412821** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Cure ADSSL1** · enrollment: 2 (estimated)

## Conditions studied

- Adenylosuccinate Synthase 1 Deficient Myopathy

## Interventions

- **DRUG:** adenylosuccinic acid

## Key facts

- **NCT ID:** NCT07412821
- **Lead sponsor:** Cure ADSSL1
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-26
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07412821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07412821, "A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07412821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*